Lowest Price Guaranteed
Pages
264
Last Updated
July 2026
View Count
19644
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Chronic Kidney Diseases
3.1.1. Medical Conditions Associated with Chronic Kidney Diseases
3.1.1.1. Alport Syndrome
3.1.1.2. Diabetic Nephropathy
3.1.1.3. Focal Segmental Glomerulosclerosis
3.1.1.4. Glomerulonephritis
3.1.1.5. Nephrotic Syndrome
3.1.1.6. Polycystic Kidney Disease
3.1.1.7. Hypertensive Kidney Disease
3.1.1.8. Pyelonephritis
3.1.2. Stages of Chronic Kidney Disease
3.1.3. Symptoms Associated with Chronic Kidney Disease
3.1.4. Diagnosis of Chronic Kidney Disease
3.1.5. Treatment Options for Chronic Kidney Disease
3.1.5.1. Therapeutics
3.1.5.2. Other Modalities
3.1.6. Kidney Transplant and Implications
4. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS
4.1. Chapter Overview
4.2. Drugs for Chronic Kidney Disease: Marketed and Development Pipeline
4.3. Chronic Kidney Disease: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Treatment
4.3.4. Analysis by Type of Therapy
4.3.5. Analysis by Type of Receptor
4.3.6. Analysis by Route of Administration
4.3.7. Analysis by Target Therapeutic Indication(s)
4.3.8. Analysis by Size of Developer
4.3.9. Analysis of Leading Developers
4.3.10. Analysis by Size and Location of the Players
4.3.11. Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
4.3.12. Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
4.3.13. Geographical Landscape
5. PRODUCT CLINICAL COMMERCIAL ATTRACTIVENESS
5.1. Chapter Overview
5.2. Methodology
5.2.1. Assumptions and Key Parameters
5.3. Affiliated Insights
5.3.1. Clinical and Commercial Attractiveness Analysis: Anemia
5.3.2. Clinical and Commercial Attractiveness Analysis: Diabetic Nephropathy and Nephrotic Syndrome
5.3.3. Clinical and Commercial Attractiveness Analysis: Focal Segmental Glomerulosclerosis
5.3.4. Clinical and Commercial Attractiveness Analysis: Lupus Nephritis and Pyelonephritis
5.3.5. Clinical and Commercial Attractiveness Analysis: IgA Nephropathy
5.3.6. Clinical and Commercial Attractiveness Analysis: CKD (Indication Unspecified)
6. CHRONIC KIDNEY DISEASE: UNMET NEEDS ANALYSIS
6.1. Chapter Overview
6.2. Unmet Needs Analysis in Chronic Kidney Disease Market
6.2.1. Analysis of Data from Patient Blogs
6.2.1.1. Methodology
6.2.1.2. Key Insights
6.2.2. Analysis of Data from Published Literature
6.2.2.1. Methodology
6.2.2.2. Key Insights
6.2.3. Analysis of Data from Social Media Platforms
6.2.3.1. Methodology
6.2.3.2. Key Insights
6.2.4. Expert opinions
6.2.4.1. Titte Srinivas, Intermountain Medical Centre
6.2.4.2. Brian Clement, Hippocrates Health Institute
6.2.4.3. Frank Brennan, Palliative Care Physician
6.2.4.4. Sarah Brook, Renal Dietitian, Salford Royal NHS Foundation Trust
6.2.4.5. Joseph Selvanayagam, Medical Researcher, Flinders University
6.2.4.6. Vanessa Rojas-Bautista, UC Irvine Health
6.2.5. Summary of Key Unmet Needs in Chronic Kidney Disease
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.1.1. Assumptions and Key Parameters
7.2. Company Competitiveness Analysis: Key Insights
7.2.1. Key Players: North America
7.2.2. Key Players: Europe
7.2.3. Key Players: Asia Pacific
8. KOL ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.4. Prominent Key Opinion Leaders
8.4.1. Geographical Distribution
8.5. Most Active Key Opinion Leaders
8.5.1. KOL Profiles: Dennis Andress
8.5.2. KOL Profile: Geoffrey A Block
8.5.3. KOL Profile: Glenn Chertow
8.5.4. KOL Profile: Steven Fishbane
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Therapeutics for Chronic Kidney Disease: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Chronic Kidney Disease Market: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Most Active Players
10.3.5. Analysis by Most Active Investors
10.4. Concluding Remarks
11. APPENDIX 1: TABULATED DATA
11.1. Chapter Overview
11.2. Key Takeaways
12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 1.1 Chronic Kidney Disease: Scope and Competitive Insights
Figure 3.1 Epidemiology of Chronic Kidney Disease
Figure 3.2 Factors Involved in the Progression of Diabetic Nephropathy
Figure 3.3 Symptoms of Chronic Kidney Disease
Figure 3.4 Diagnostic Techniques for Chronic Kidney Disease
Figure 3.5 Treatment Options for Chronic Kidney Disease
Figure 3.6 ACE Inhibitors: Mechanism of Action
Figure 3.7 Statins: Mechanism of Action
Figure 3.8 Loop Diuretics: Mechanism of Action
Figure 3.9 Thiazide Diuretics: Mechanism of Action
Figure 3.10 Complications Associated with Kidney Transplants
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Molecule
Figure 4.3 Pipeline Analysis: Distribution by Type of Treatment
Figure 4.4 Pipeline Analysis: Distribution by Type of Therapy
Figure 4.5 Pipeline Analysis: Distribution by Type of Receptor
Figure 4.6 Pipeline Analysis: Distribution by Route of Administration
Figure 4.7 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Figure 4.8 Pipeline Analysis: Distribution by Size of Employee Base of Developer
Figure 4.9 Pipeline Analysis: Leading Players
Figure 4.10 Pipeline Analysis: Distribution by Size and Location
Figure 4.11 Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
Figure 4.12 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Figure 4.13 Geographical Landscape
Figure 5.1 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Anemia
Figure 5.2 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Diabetic Nephropathy and Nephrotic Syndrome
Figure 5.3 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Focal Segmental Glomerulosclerosis
Figure 5.4 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Lupus Nephritis and Pyelonephritis
Figure 5.5 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for IgA Nephropathy
Figure 5.6 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for CKD (Indication Unspecified)
Figure 6.1 Unmet Needs Analysis: Overview of the Methodology
Figure 6.2 Unmet Needs in the Chronic Kidney Disease Market: Word Cloud Analysis of Data from Patient Blogs
Figure 6.3 Chronic Kidney Disease: Unmet Needs Highlighted in Published Literature
Figure 6.4 Unmet Needs in Chronic Kidney Disease: Social Media Platforms, Sentiment Analysis
Figure 6.5 Unmet Needs in Chronic Kidney Disease: Word Cloud Analysis of Data from Social Media Tweets
Figure 6.6 Unmet Needs in Chronic Kidney Disease, Social Media Analysis: Indication Specific Word Clouds
Figure 6.7 Unmet Needs in Chronic Kidney Disease, Social Media Analysis: Indication Specific Word Clouds
Figure 6.8 Chronic Kidney Disease: Key Unmet Needs
Figure 7.1 Company Competitiveness Analysis: North America
Figure 7.2 Company Competitiveness Analysis: Europe
Figure 7.3 Company Competitiveness Analysis: Asia Pacific
Figure 8.1 KOL Analysis: Dot-Plot of Principal Investigators
Figure 8.2 KOL Analysis: Geographical Location of Principal Investigators
Figure 8.3 KOL Analysis: Most Active Key Opinion Leaders
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Most Active Players
Figure 9.4 Partnerships and Collaborations: Regional Distribution
Figure 9.5 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Figure 10.2 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Figure 10.5 Chronic Kidney Disease: Summary of Investments, January 2010-July 2018 (USD Million)
Figure 10.6 Funding and Investment Analysis: Most Active Players
Figure 10.7 Funding and Investment Analysis: Most Active Investors
Figure 10.8 Funding and Investment Summary
Table 3.1 Indicative Values of Focal Segmental Glomerulosclerosis
Table 3.2 Stages of Chronic Kidney Disease
Table 4.1 Chronic Kidney Disease: Marketed and Development Pipeline
Table 8.1 KOL Analysis: List of Principal Investigators
Table 8.2 KOL Analysis: List of Universities and Hospitals
Table 8.3 KOL Analysis: Scoring System
Table 8.4 KOL Profile: Dennis Andress, Clinical Trials
Table 8.5 KOL Profile: Dennis Andress, Published Literature
Table 8.6 KOL Profile: Geoffrey A Block, Clinical Trials
Table 8.7 KOL Profile: Geoffrey A Block, Published Literature
Table 8.8 KOL Profile: Glenn Chertow, Clinical Trials
Table 8.9 KOL Profile: Glenn Chertow, Published Literature
Table 8.10 KOL Profile: Steven Fishbane, Clinical Trials
Table 8.11 KOL Profile: Steven Fishbane, Published Literature
Table 9.1 Novel Therapeutics for Chronic Kidney Disease: Partnerships and Collaborations, 2015-2018
Table 10.1 Chronic Kidney Disease Market: Funding and Investments, 2010-2018
Table 10.2 Funding and Investment Analysis: Summary of Investments
Table 11.1 Chronic Kidney Disease: Summary of the Competitive Insights
Table 12.1 Epidemiology of Chronic Kidney Disease
Table 12.2 Pipeline Analysis: Distribution by Phase of Development
Table 12.3 Pipeline Analysis: Distribution by Type of Molecule
Table 12.4 Pipeline Analysis: Distribution by Type of Treatment
Table 12.5 Pipeline Analysis: Distribution by Type of Therapy
Table 12.6 Pipeline Analysis: Distribution by Type of Receptor
Table 12.7 Pipeline Analysis: Distribution by Route of Administration
Table 12.8 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Table 12.9 Pipeline Analysis: Distribution by Size of Developer
Table 12.10 Pipeline Analysis: Leading Players
Table 12.11 Pipeline Analysis: Distribution by Size and Location of the Players
Table 12.12 Heptagon Representation: Distribution by Type of Indication and Development Stage
Table 12.13 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Table 12.14 Geographical Landscape Analysis: Distribution by Developers and their Headquarters
Table 12.15 Unmet Needs in Chronic Kidney Disease: Needs Highlighted in Published Literature
Table 12.16 Unmet Needs in Chronic Kidney Disease: Social Media Platforms, Sentiment Analysis
Table 12.17 Unmet Needs in Chronic Kidney Disease, Social Media Analysis: Indication Specific Tweets
Table 12.18 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Table 12.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.20 Partnerships and Collaborations: Most Active Players
Table 12.21 Partnerships and Collaborations: Regional Distribution
Table 12.22 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 12.23 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Table 12.24 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Table 12.25 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Table 12.26 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Table 12.27 Chronic Kidney Disease: Summary of Investments, January 2010-July 2018 (USD Million)
Table 12.28 Funding and Investment Analysis: Most Active Players
Table 12.29 Funding and Investment Analysis: Most Active Investors
Table 12.30 Funding and Investment Summary
Please reach out to our team for more details.